Novedades en el tratamiento de la enfermedad de Crohn

Reynolds, 2007, Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis, Pharmacotherapy, 27, 1693, 10.1592/phco.27.12.1693 Hanauer, 2010, A randomized placebo-controlled trial of abatacept for moderately-to-severely active Crohn's disease, Gastroenterology, 138, A649 Smith, 2010, Naltrexone therapy improves activity and promotes mucosal healing in active Crohn's disease: a placebo-controlled trial, Gastroenterology, 138, A646 Mani, 2009, New insights into the role of endogenous opioids in the pathogenesis of gastrointestinal and liver disease, Gut, 58, 893, 10.1136/gut.2007.141648 Eksteen, 2010, GSK-1605786, a selective small-molecule antagonist of the CCR9 chemokine receptor for the treatment of Crohn?s disease, Drugs, 13, 472 Keshav, 2010, Chemokine receptor antagonist CCX282-B (Traficet-En™) maintained remission of Crohn's disease in PROTECT-1 study, Gastroenterology, 138, A647 Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probióticos para el mantenimiento de la remisión en la enfermedad de Crohn (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 Número 1. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2007 Issue 1. Chichester, UK: John Wiley & Sons, Ltd.). Chaparro, 2010, Safety of thiopurine therapy in inflammatory bowel disease (IBD): long-term follow-up study of 3,900 patients, Gastroenterology, 138, AW1193 Israelí, 2010, Promotion of CD4+CD25+FOXP3+ regulatory cells by oral administration of locally acting delayed release low-dose 6MP formulation alleviated Crohn's disease: results of phase I/II clinical trial, Gastroenterology, 138, AT1241 Ford, 2010, Efficacy of biologics in Crohn's disease (CD): a meta-analysis of randomized controlled trials looking at inducing remission in active disease and preventing relapse rates in quiescent disease, Gastroenterology, 138, AT1245 Regueiro, 2009, Gastroenterology, 136, 716, 10.1053/j.gastro.2008.10.051 Regueiro, 2010, 4.5 yr follow-up of patients enrolled in the randomized controlled trial (RCT) of infliximab (Inf) for prevention of postoperative Crohn's disease (CD), Gastroenterology, 138, AW1298 Fernández-Blanco, 2010, Adalimumab in the prevention of postoperative recurrence of Crohn's disease, Gastroenterology, 138, AW1291 Etchevers, 2010, Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach, Drugs, 70, 109, 10.2165/11533700-000000000-00000 Van Moerkercke, 2010, High infliximab trough levels are associated with mucosal healing in Crohn's disease, Gastroenterology, 138, A405 Steenholdt, 2010, Discriminating between response types in infliximab-treated patients with Crohn's disease: sensitivity and specificity of combined assessment of infliximab trough levels and anti-drug antibodies, Gastroenterology, 138, AW1270 Colombel, 2010, Infliximab, azathioprine, or combination therapy for Crohn's disease, N Engl J Med, 15, 1383, 10.1056/NEJMoa0904492 Feagan, 2010, Methotrexate for the prevention of antibodies to infliximab in patients with Crohn's disease, Gastroenterology, 138, AS1051 Chaparro, 2010, Effectiveness of infliximab after adalimumab failure in Crohn's disease, Gastroenterology, 138, AW1300 Chaparro, 2010, Long-term durability of response to adalimumab treatment in Crohn's disease, Gastroenterology, 138, AW1275 Schreiber, 2006, CLASSIC-I study the efficacy of adalimumab, Gastroenterology, 130, 1929, 10.1053/j.gastro.2006.03.050 Sandborn, 2007, Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial, Gut, 56, 1232, 10.1136/gut.2006.106781 Li, 2010, Evaluation of potential correlations between serum adalimumab concentration and remission in patients with Crohn's disease in Classic I and II, Gastroenterology, 138, A741 Van Assche, 2010, Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab. the prospective randomized Switch study, Gastroenterology, 138, A645 Reinisch, 2010, Prediction of long-term clinical remission for adalimumab-treated patients with Crohn's disease by identification of appropriate dichotomizing points for SES-CD, Gastroenterology, 138, A41a Colombel, 2010, Adalimumab treatmen results in deep remission for patients with modrate to severe ileocolonic Crohn's disease: results from EXTEND, Gastroenterology, 138, AT1239 Rutgeerts, 2010, Early mucosal healing status predicts long-term clinical benefits for adalimumab-treated patients with moderate to severe Crohn's disease, Gastroenterology, 138, A644 Sandborn, 2010, Patients with Crohn's disease treated with certolizumab pegol experienced long-term remission regardless of prior TNF-α inhibitor exposure (PRECiSE 4 study), Gastroenterology, 138, A44 Elvanides, 2010, Natalizumab is effective in the treatment of moderate to severe Crohn's disease unresponsive to anti-TNF agents, Gastroenterology, 138, AW1320